D-4-chloro-17 beta-hydroxy-3-oxo-17 alpha-methylandrosta-1,4-diene

Subscribe to Selected New Research on D-4-chloro-17 beta-hydroxy-3-oxo-17 alpha-methylandrosta-1,4-diene

21 relevant articles (2 outcomes, 2 trials/studies) found for this Bio-Agent

Also Known As:

4-chloro-methandienone; CDMT; Oral Turinabol; Turinabol-oral; dehydrochlormethyltestosterone; 4-chloro-17 alpha-methyl-17 beta-hydroxy-1,4- androstadiene-3-one

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 59

D-4-chloro-17 beta-hydroxy-3-oxo-17 alpha-methylandrosta-1,4-diene: 21

Hormones, Hormone Substitutes, and Hormone Antagonists

Hormones: 46253

Gonadal Hormones: 260

Gonadal Steroid Hormones: 2275

Testosterone Congeners: 17

Testosterone: 9499

D-4-chloro-17 beta-hydroxy-3-oxo-17 alpha-methylandrosta-1,4-diene: 21

Experts

1.	Renshaw, A: 1 article (05/2000)

Related Diseases

1.	Neoplasms (Cancer) 07/01/1998 - "We have shown that: (1) MT-transgenic and -null mice have altered tissue MT protein levels; (2) MT-transgenic and -null mice appear to be normal in other detoxifying systems examined, except for slight alterations in tissue Zn concentration; (3) MT does not appear to inhibit Cd absorption from the gastrointestinal tract, nor affect Cd tissue distribution; (4) MT reduces the elimination of Cd from liver; (5) MT protects against acute inorganic Cd-induced lethality and hepatotoxicity, and the mechanism of the protection appears to be due to its ability to sequester Cd in the cytosol, thus reducing the amount of Cd in critical organelles; (6) MT modulates Cd-induced expression of protooncogene(c-jin) and tumor suppress genes (p53) in mouse liver; (7) MT does not protect against CdMT-induced acute renal injury, and Zn-induced protection against CdMT-induced acute nephrotoxicity does not appear to be mediated through MT; (8) Chronic Cd administration produces renal injury inb MT-null mice, indicating that Cd-induced nephrotoxicity is not necessarily mediated through the CdMT complex; (9) MT protects against chronic CdC12 nephropathy, suggesting that intracellular MT is an important adaptive mechanism decreasing CdC12 nephrotoxicity, and that a single injection of CdMT may not be a good model to study chronic Cd nephropathy; (10) genetic background of mouse strains, rather than constitutive MT levels, is a more important determinant for Cd-induced acute testicular injury. " Order ALL the reference details at left...
2.	Body Weight (Weight, Body) 06/01/1992 - "In the factorial design two levels of Zn (0 and 25 mg/kg body weight), two levels of Cu (0 and 12.5 mg/kg), and two levels of CdMT (0.1 and 0.4 mg of Cd/kg) were used as varied factors. " 01/08/1996 - "Protection against the development of nephrotoxicity following the administration of cadmium-metallothionein (CdMT) at a dose of 0.4 mg Cd per kg body weights was studied in streptozotocin (STZ)-induced diabetic rats. " Order ALL the reference details at left...
3.	Proteinuria 10/01/1992 - "A prominent increase of proteinuria appeared at 24-48 h after the challenge of CdMT. " 10/01/1992 - "In Group A, calciuria, proteinuria, metallothioneinuria and enzymuria was induced by CdMT. " 03/15/1990 - "The appearance of Mg and Ca excretion peaks at an early stage after CdMT injection makes it likely that this effect is an early event in the process of development of cellular damage and does not merely represent unspecific cellular damage giving rise to proteinuria." 09/01/1987 - "It is known that a disturbance of Ca metabolism could influence the membrane stability and such a change may contribute to explaining the proteinuria characteristic of CdMT nephrotoxicity. " 05/01/1987 - "In contrast, in animals repeatedly pretreated with CdMT according to 1), no proteinuria was observed after administration of the same single doses of 109CdMT. " Order ALL the reference details at left...
4.	Necrosis 08/01/1999 - "In contrast to a single injection of CdMT that produces proximal tubular necrosis, chronic injection of CdMT results in tubular cell apoptosis in both wild-type and MT-null mice. " 11/01/1998 - "In contrast, acute CdMT injection produced severe proximal tubule necrosis as the major feature of its toxicity. " 04/01/1996 - "CdMT also induced a similar dose-dependent proximal tubular cell necrosis in both control and MT-transgenic mice in a dose-dependent manner. " 03/01/1996 - "In contrast to CdCl2-induced hepatotoxicity, MT-null mice were equally susceptible as controls to the Cd-MT (CdMT) (0.1-0.4 mg Cd/kg i.v.) nephrotoxicity, as evidenced by similar increases in urinary protein (up to 30-fold) and glucose excretion (up to 60-fold), as well as similar extent of proximal tubular necrosis. " 01/01/1987 - "These marked changes in renal calcium metabolism occurred in the absence of mitochondrial damage, changes in total, Na/K or Mg-stimulated ATPase activities, renal ATP levels, membrane 45Ca2+ transport or overt tubule cell necrosis during an 8 hour period following CdMT injection. " Order ALL the reference details at left...
5.	Leiomyosarcoma 05/01/2000 - "Intratesticular leiomyosarcoma in a young man after high dose doping with oral-turinabol. " 10/15/1999 - "Intratesticular leiomyosarcoma in a young man after high dose doping with Oral-Turinabol: a case report." Order ALL the reference details at left...

Related Drugs and Biologics

1.	cadmium-metallothionein complex
2.	cadmium-binding protein
3.	Streptozocin (Streptozotocin)
4.	Cadmium
5.	Cadmium Chloride (Cadmium Dichloride)
6.	Glucose (Dextrose)
7.	Thioacetamide (Thioacetamid)
8.	Muramidase (Lysozyme)
9.	Metallothionein
10.	Insulin (Novolin)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>